Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline
This strategic investment strengthens Cohance's integrated oligonucleotide platform
Based out of Boston, Vivek will build on the foundation created by Vaidheesh, and will help build a stronger customer connect and further drive global expansion of the platform
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Subscribe To Our Newsletter & Stay Updated